Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)

Table 2 Distribution of predefined risk factors in the low- and non-low-risk groups (all evaluable patients)

Variable	Low-risk group^a (N = 154)	Non-low-risk group^a (N = 68)^b	Total (N = 222)
N0	117 (76%)	19 (28%)	136 (61%)
N1a	37 (24%)	49 (72%)	86 (39%)
pT3	3 (2%)	6 (9%)	9 (4%)
Grade 3	12 (8%)	36 (53%)	48 (22%)
Lympho-vascular invasion	7 (5%)	43 (63%)	50 (23%)
ER <50% and PgR < 50%	–	1 (1%)	1 (0%)
Ki67 > 30%	10 (6%)	19 (28%)	29 (13%)
Risk factors, mean (range)	0.2 (0–1)	1.6 (1–3)	0.6 (0–3)

Data are n (%) unless otherwise indicated
^aDefinitions. Low-risk: N0 and ≤1 predefined risk factor, or N1a with no predefined risk factor. Non-low-risk: N0 and ≥2 predefined risk factors, or N1a with ≥1 predefined risk factors (Comment: These classifications were fixed in the protocol but not disclosed to study participants)
^bOne evaluable patient withdrew from the study before the second tumor board provided a recommendation

ISSN: 1471-2407